Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2026)
Insight Molecular Diagnostics' (IMDX) quarterly EBT Margin came in at 13790.62% in Q1 2026, down 1347262.0% year-on-year from N/an in Q1 2025, and down 1016.32% quarter-over-quarter from 1505.0% in Q4 2025.
Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2026) Analysis & Trends
Insight Molecular Diagnostics has disclosed EBT Margin across 7 years of filings, most recently posting 13790.62% for Q1 2026.
- EBT Margin for Q1 2026 came in at 13790.62%, down 1347262.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 418.73% (down 15146.0% YoY), and the FY2025 annual result was 260.1%, up 41715.0% from the prior year.
- EBT Margin came in at 13790.62% for Q1 2026 at Insight Molecular Diagnostics, down from 1505.0% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 2006.4% in Q1 2023 to a low of 13790.62% in Q1 2026.
- The 5-year median for EBT Margin is 1900.0% (2025), against an average of 3184.12%.
- Across the five-year window, EBT Margin jumped 750294 bps in 2025 and sank 1347262 bps in 2026, its largest moves.
- Insight Molecular Diagnostics' EBT Margin stood at 4385.77% in 2022, then slipped by 16 bps to 5092.99% in 2023, then soared by 119 bps to 987.55% in 2024, then surged by 52 bps to 1505.0% in 2025, then tumbled by 1016 bps to 13790.62% in 2026.
- The last three EBT Margin figures came in at 13790.62% (Q1 2026), 1505.0% (Q4 2025), and 4249.23% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 29,902.70 Bn | 29,902.24 Bn | 1.11 Bn | -6.95% |
| 2 | Thermo Fisher Scientific | 175.99 Bn | 172.74 Bn | 7.74 Bn | 15.76% |
| 3 | Danaher | 129.87 Bn | 124.18 Bn | 3.59 Bn | 20.75% |
| 4 | Idexx Laboratories | 44.75 Bn | 44.55 Bn | 722.74 Mn | 31.16% |
| 5 | Agilent Technologies | 37.52 Bn | 35.72 Bn | 990.00 Mn | 22.23% |
| 6 | Iqvia Holdings | 30.91 Bn | 28.94 Bn | 1.36 Bn | 7.90% |
| 7 | Natera | 30.21 Bn | 29.11 Bn | 696.04 Mn | -12.17% |
| 8 | Illumina | 24.19 Bn | 23.04 Bn | 721.00 Mn | 14.39% |
| 9 | Mettler Toledo International | 23.12 Bn | 23.06 Bn | 555.82 Mn | 22.14% |
| 10 | Insight Molecular Diagnostics | 4.34 Mn | -24.59 Mn | 15,000.00 | -13,790.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13,790.63% |
| Dec 31, 2025 | 1,505.00% |
| Sep 30, 2025 | -4,249.23% |
| Jun 30, 2025 | -1,900.00% |
| Mar 31, 2025 | -318.01% |
| Dec 31, 2024 | 987.55% |
| Sep 30, 2024 | -11,752.17% |
| Jun 30, 2024 | -4,453.85% |
| Mar 31, 2024 | -5,186.93% |
| Dec 31, 2023 | -5,092.99% |
| Sep 30, 2023 | -1,512.59% |
| Jun 30, 2023 | -1,799.78% |
| Mar 31, 2023 | 2,006.40% |
| Dec 31, 2022 | -4,385.77% |
| Sep 30, 2022 | -2,713.43% |
| Jun 30, 2022 | -575.53% |
| Mar 31, 2022 | -898.16% |
| Dec 31, 2021 | -997.16% |
| Sep 30, 2021 | -1,402.44% |
| Jun 30, 2021 | -605.27% |